Full CoverageTop news
FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
By Tricia Neuman & Juliette Cubanski
Third member of FDA expert committee resigns over Alzheimer's decision
By Andrew Joseph
The FDA's Approval Of Aduhelm: Potential Implications Across A Wide Range Of Health Policy Issues And Stakeholders
By Rachel E Sachs
All coverage
New Alzheimer’s drug aducanumab: cost, side effects, timeline and other questions answered
By Jacqueline Howard
Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug
By Berkeley Lovelace & Berkeley Lovelace Jr.
Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug (Published 2021)
By Pam Belluck & Rebecca Robbins
